An Open-label, Multicenter, Randomized Phase II Study Evaluating the Safety and Efficacy of Docetaxel in Combination With IMC 1121B or IMC 18F1 or Without Investigational Therapy as Second line Therapy in Patients With Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy

Conditions

Bladder | Kidney | Other Urinary

What is the purpose of this trial?

To evaluate the progression-free survival (PFS) in patients with metastatic transitional cell carcinoma (TCC) when treated with docetaxel monotherapy or docetaxel in combination with either the monoclonal antibody ramucirumab (IMC-1121B) drug product (hereafter referred to as ramucirumab DP) or IMC-18F1.


Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Imclone Systems, Inc.
Dates:
03/19/2013
Last Updated:
Study HIC#:
1211011153